Please login to the form below

Not currently logged in
Email:
Password:

treatment-resistant depression

This page shows the latest treatment-resistant depression news and features for those working in and with pharma, biotech and healthcare.

J&J gets EU approval for depression nasal spray Spravato

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing. Johnson &Johnson can market its treatment-resistant depression drug Spravato on both sides of the Atlantic, now that the EMA has followed ... Approximately half of all Spravato patients achieved

Latest news

  • Sage slides off a MOUNTAIN as depression drug flunks trial Sage slides off a MOUNTAIN as depression drug flunks trial

    SAGE-217 is an oral follow-up to Sage’s  Zulresso (brexanolone) for postpartum depression (PPD), which was approved by the FDA in March and is delivered by a ... that is used as an add-on to standard drugs for treatment-resistant depression.

  • J&J’s ponesimiod tops Aubagio in head-to-head MS trial J&J’s ponesimiod tops Aubagio in head-to-head MS trial

    The company does however have a resurgent central nervous system (CNS) therapeutic category following the approval of Spravato(esketamine), a nasal spray for treatment-resistant depression that J&J reckons can

  • Stung by critics, J&J says antidepressant Spravato saves money Stung by critics, J&J says antidepressant Spravato saves money

    Responds to ICER cost effectiveness ruling. Johnson &Johnson insists its nasal spray antidepressant Spravato can reduce the cost of caring for treatment-resistant depression (TRD) compared to oral drugs, in a ... label prescription and coverage of a

  • J&J’s Spravato breaks depression drought at FDA J&J’s Spravato breaks depression drought at FDA

    The FDA has approved Johnson &Johnson’s Spravato for treatment-resistant depression, making it the first new-mechanism antidepressant to be licensed in decades. ... At the moment the only FDA-approved drug for treatment-resistant depression is Eli

  • FDA panel backs J&J’s new-class antidepressant FDA panel backs J&J’s new-class antidepressant

    Johnson &Johnson could be just weeks away from approval of the first new drug class for depression in decades, giving a new option for patients with severe, treatment-resistant symptoms. ... The agency has awarded J&J two breakthrough designations for

More from news
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

  • War on drugs: the use of controlled substances in medicine War on drugs: the use of controlled substances in medicine

    the treatment of medical conditions; medical conditions such as mental disorders which are now among the leading causes of ill-health and disability worldwide. ... Ketamine has shown efficacy in the treatment of mental health conditions with the FDA

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics